DALRADA FINCL CORP - DFCO STOCK NEWS

Dalrada Corporation (OTCQB: DFCO) has appointed Mr. William "Bill" Davidson as an Advisor to its Clean Energy Board, focusing on technology and business strategy. Mr. Davidson brings over 35 years of leadership experience in telecommunications, software, and semiconductors. Currently COO of Amionx and founder of Sapienter Group, he aims to leverage his industry expertise for Dalrada's growth. Chairman Brian Bonar expresses optimism about Davidson’s strategic insights as Dalrada continues innovating within the clean energy sector.

Dalrada Financial Corp. (DFCO) reported a remarkable Q2 2022 revenue of $5,447,264, representing a 1,096% increase compared to Q2 2021 ($455,517). The company's growth was driven by its healthcare and technology segments, with COVID-19 diagnostic testing revenues hitting $4,385,798. Additionally, the technology division saw a 143% revenue rise. Dalrada's subsidiaries, including Likido and Dalrada Precision, also reported significant growth, with Likido achieving a 681% revenue increase. CEO Brian Bonar emphasized the company's adaptability and commitment to innovation amidst ongoing challenges.

Dalrada Corporation (OTCQB: DFCO) has appointed Dr. Aboo Nasar as the new Medical Director for its subsidiary, Dalrada Health's Sòlas Rejuvenation + Wellness center in San Diego. With over 22 years of experience, Dr. Nasar is board-certified in Holistic and Anti-Aging Functional Regenerative Medicine. He has founded three successful medical spas and aims to enhance personalized healthcare services. The North American precision medicine market is growing rapidly, set to exceed USD 23.2 billion by 2027, providing a promising backdrop for Sòlas' innovative health services.

Dalrada Corporation (DFCO) announced a securities purchase agreement for issuing convertible debentures totaling $3,000,000. The first debenture valued at $2,000,000 was acquired on February 7, 2022, while the second, worth $1,000,000, will follow after a registration statement with the SEC. The financing supports Dalrada’s expansion in key growth markets including Technology, Energy, and Health, particularly enhancing its Empower Genomics and Likido Limited subsidiaries.

Dalrada Corporation (OTCQB: DFCO) appreciates its investors and staff for their support in 2021, highlighting significant expansions into clean energy, healthcare, and technology. The company has reported impressive growth metrics, including a 189% year-over-year revenue increase and a 506% quarter-to-quarter revenue surge as of September 30, 2021. Additionally, Dalrada aims to tackle global challenges through impactful innovations across its subsidiaries. With a focus on digital transformation and personalized healthcare, Dalrada is well-positioned for future growth in the evolving market landscape.

Dalrada Corporation (OTCQB: DFCO) collaborates with Lenovo and Iceotope to develop an ultra-low power, liquid-cooled technology for data centers. This new system aims to address environmental concerns by recycling excess heat for district heating, providing a dual benefit of energy cost savings and creating new revenue streams. By utilizing Likido®AD absorption chillers, the partnership promises ultra-low power usage effectiveness (PUE) ratios, transforming data center operations while reducing water and energy consumption. The global liquid cooling market is projected to grow significantly, indicating strong industry demand.

Dalrada Corporation (DFCO) has announced the addition of two new directors, Amy Wing Scannell, Esq., and Vincent Monteparte, to its Board of Directors. Scannell brings expertise in corporate compliance and investments, while Monteparte has extensive experience in venture capital and investment banking, managing significant transactions. CEO Brian Bonar emphasized the strategic importance of these appointments as Dalrada prepares to expand into high-growth sectors and plans to uplist to NASDAQ, aiming to strengthen its market position and governance.

Dalrada Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as President of its subsidiary, Dalrada Health. With over 35 years in the healthcare sector, his experience is expected to bolster the company’s growth and expansion initiatives. Dalrada Health is involved in multiple segments, including GlanHealth™ and Pala Diagnostics, and has achieved significant milestones in healthcare services, including the launch of COVID-19 on-site testing. The global healthcare services market is projected to grow at a CAGR of 7% to $9,725.4 billion by 2023, positioning Dalrada favorably in this evolving landscape.

Dalrada Corporation (DFCO) has reported impressive financial results for Q1 ending September 30, 2021, with revenues of $4,602,353, a remarkable 506% increase from $759,393 in Q1 2020. Gross profit surged to $3,398,018, up 546% from $525,965 the previous year. The stockholder deficit decreased by 48%. Dalrada's strong performance comes alongside growth in its healthcare and technology divisions, despite increased operating expenses due to various expansions and compensations.